215 related articles for article (PubMed ID: 28544693)
1. Hepatocellular carcinoma and direct-acting antivirals: A never ending story?
Calvaruso V; Craxì A
Liver Int; 2017 Jun; 37(6):812-814. PubMed ID: 28544693
[No Abstract] [Full Text] [Related]
2. Damned if you do, damned if you don't: The evolving story of de novo and recurrent hepatocellular carcinoma amongst those treated with direct-acting antivirals for hepatitis C virus.
Yang JD; Leise MD
Liver Int; 2017 Jun; 37(6):809-811. PubMed ID: 28544691
[No Abstract] [Full Text] [Related]
3. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma.
Mehta N; Yao FY
Liver Transpl; 2017 Dec; 23(12):1596-1600. PubMed ID: 29024442
[No Abstract] [Full Text] [Related]
4. Pro: Direct-acting antivirals are associated with occurrence and recurrence of hepatocellular carcinoma.
Trotter JF
Liver Transpl; 2017 Dec; 23(12):1593-1595. PubMed ID: 29024516
[No Abstract] [Full Text] [Related]
5. Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.
Stournaras E; Neokosmidis G; Stogiannou D; Protopapas A; Tziomalos K
Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1277-1282. PubMed ID: 30179906
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
[TBL] [Abstract][Full Text] [Related]
7. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851
[TBL] [Abstract][Full Text] [Related]
8. Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma.
Tholey DM; Ahn J
Gastroenterol Clin North Am; 2015 Dec; 44(4):761-73. PubMed ID: 26600218
[TBL] [Abstract][Full Text] [Related]
9. Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients.
Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Hashem MB; Hassan EM; Salah A; Omran DA; Elbaz TM
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):75-79. PubMed ID: 30199473
[TBL] [Abstract][Full Text] [Related]
10. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
Kwong AJ; Kim WR; Flemming JA
Hepatology; 2018 Oct; 68(4):1288-1297. PubMed ID: 29672886
[TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy.
Villani R; Vendemiale G; Serviddio G
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30583555
[TBL] [Abstract][Full Text] [Related]
12. The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico.
Méndez-Sánchez N
Ann Hepatol; 2012; 11(4):550-1. PubMed ID: 22700637
[No Abstract] [Full Text] [Related]
13. Management of recurrent hepatitis C virus after liver transplantation.
Jiménez-Pérez M; González-Grande R; Rando-Muñoz FJ
World J Gastroenterol; 2014 Nov; 20(44):16409-17. PubMed ID: 25469009
[TBL] [Abstract][Full Text] [Related]
14. Editorial - HCC in HCV patients and the direct acting antivirals: is there really a link?
Marrone A; Franci G; Perrella A; Nevola R; Chianese A; Adinolfi LE; Sasso FC; Rinaldi L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):983-987. PubMed ID: 32017007
[No Abstract] [Full Text] [Related]
15. Things fall apart with hepatocellular carcinoma and direct-acting antivirals.
Kutala B; Valla D; Marcellin P
Expert Opin Drug Saf; 2018 Feb; 17(2):107-109. PubMed ID: 29137488
[No Abstract] [Full Text] [Related]
16. Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?
Cabibbo G; Celsa C; Cammà C; Craxì A
Liver Int; 2018 Dec; 38(12):2108-2116. PubMed ID: 29935096
[TBL] [Abstract][Full Text] [Related]
17. DAAs for HCV and risk of hepatocellular carcinoma: current standpoint.
Piscaglia F; Granito A; Bolondi L
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):736-738. PubMed ID: 30353852
[No Abstract] [Full Text] [Related]
18. Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.
Saraiya N; Yopp AC; Rich NE; Odewole M; Parikh ND; Singal AG
Aliment Pharmacol Ther; 2018 Jul; 48(2):127-137. PubMed ID: 29851093
[TBL] [Abstract][Full Text] [Related]
19. Rapidly growing hepatocellular carcinoma recurrence during direct-acting antiviral treatment for chronic hepatitis C.
Yamashita N; Tanimoto H; Shimoda S; Komori A; Nomura H
Clin J Gastroenterol; 2018 Dec; 11(6):497-500. PubMed ID: 29948818
[TBL] [Abstract][Full Text] [Related]
20. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]